Trial reportDiabetes care2021
Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes.
Trial report in Diabetes care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03844789 (The International Diabetes Closed Loop), which is not on this map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas in Pediatrics: A Study of t:Slim X2 With Control-IQ Technology
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Hybrid closed-loop insulin delivery improves glycaemic control compared with sensor-augmented pump therapy: A meta-analysis of 'free-living' randomised trials in type 1 diabetes.Diabetic medicine : a journal of the British Diabetic Association · 2026Pooled it
- Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling.Health technology assessment (Winchester, England) · 2024Pooled it
- Pooled it
- Automated Insulin Delivery in Adults With Type 2 Diabetes: A Nonrandomized Clinical Trial.JAMA network open · 2025Trial
- Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study.Journal of diabetes science and technology · 2023Trial
- Predictors of Time-in-Range (70-180 mg/dL) Achieved Using a Closed-Loop Control System.Diabetes technology & therapeutics · 2021Trial
- Health-Related Quality of Life and Treatment Satisfaction in Parents and Children with Type 1 Diabetes Using Closed-Loop Control.Diabetes technology & therapeutics · 2021Trial
- Postprandial Glycemic Control With Automated Insulin Delivery With Control-IQ Technology: The Impact of Meal Composition.Diabetes, obesity & metabolism · 2026Article
- Updated glucose management indicator (GMI) better aligns with HbADiabetologia · 2026Article
- Sensor-based digital health technologies to capture endpoints in recent clinical trials: a scoping review.NPJ digital medicine · 2026Article
- Improvement in Glucometric Outcomes After Control-IQ Initiation in Pediatric and Adolescent Type 1 Diabetes Patients: The Impact of Basal Time in Range.International journal of molecular sciences · 2025Article
- Evaluation of Glycemia Risk Index and Continuous Glucose Monitoring Outcomes Following the Transition to an Advanced Hybrid Closed-Loop System in Type 1 Diabetes.Advances in therapy · 2025Article
- Registration and Real-Life Studies on Automated Insulin Delivery Systems.Journal of diabetes science and technology · 2025Review
- Does the OP5 Automated Insulin Delivery System Close the Gap in Glycemic Control Between White and Black Youth with Type 1 Diabetes?Diabetes technology & therapeutics · 2025Article
- Automated Insulin Delivery Systems in Pediatric Type 1 Diabetes: A Narrative Review.Journal of diabetes science and technology · 2024Review
- Safety and Psychological Outcomes of Tandem t:Slim X2 Insulin Pump with Control-IQ Technology in Children, Adolescents, and Young Adults with Type 1 Diabetes: A Systematic Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- The Hybrid Closed-Loop System Tandem t:slim X2™ with Control-IQ Technology: Expert Recommendations for Better Management and Optimization.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes.Diabetes technology & therapeutics · 2024Article
- Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review.Communications medicine · 2023Article
- New therapies towards a better glycemic control in youths with type 1 diabetes.Pharmacological research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 1 country.
Funding
Abstract
objectiveTo further evaluate the safety and efficacy of the Control-IQ closed-loop control (CLC) system in children with type 1 diabetes. RESEARCH DESIGN AND
methodsAfter a 16-week randomized clinical trial (RCT) comparing CLC with sensor-augmented pump (SAP) therapy in 101 children 6-13 years old with type 1 diabetes, 22 participants in the SAP group initiated use of the CLC system (referred to as SAP-CLC cohort), and 78 participants in the CLC group continued use of CLC (CLC-CLC cohort) for 12 weeks.
resultsIn the SAP-CLC cohort, mean percentage of time in range 70-180 mg/dL (TIR) increased from 55 ± 13% using SAP during the RCT to 65 ± 10% using CLC (
conclusionsThis further evaluation of the Control-IQ CLC system supports the findings of the preceding RCT that use of a closed-loop system can safely improve glycemic control in children 6-13 years old with type 1 diabetes from the 1st day of use and demonstrates that these improvements can be sustained through 28 weeks of use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.